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Introduction
FEX is a non-sedating H 1 receptor antagonist used clinically for the treatment of seasonal allergies. FEX is metabolically stable; less than 5% of the dose is eliminated by metabolism in humans (Cvetkovic et al., 1999) . FEX is eliminated primarily via biliary excretion. In mice, biliary and renal clearance account for 50-70% and 10-20% of FEX total body clearance, respectively (Tahara et al., 2005) .
In vitro studies have demonstrated that cellular uptake of FEX is mediated by the 1A2 and 2B1 isoforms of human organic anion transporting polypeptide (OATP1A2 and OATP2B1, respectively); cellular efflux of FEX is mediated by human P-gp (Cvetkovic et al., 1999) . FEX concentrations in plasma, brain, kidney, and liver were elevated significantly after oral and intravenous administration to P-gp-knockout mice (Cvetkovic et al., 1999) . FEX has been used as a P-gp probe substrate for clinical drug-drug and food-drug interaction studies (Banfield et al., 2002; Shon et al., 2005) .
In rodents, FEX biliary excretion was not impaired in P-gp-or Bcrp-knockout mice, or Mrp2-deficient Eisai hyperbilirubinemic rats (Tahara et al., 2005) . These findings led to the hypothesis that one or more unidentified transport protein(s) distinct from P-gp, Mrp2, and Bcrp mediates the biliary excretion of FEX. Recent studies have suggested that species differences exist in transport mechanisms mediating biliary excretion (Zamek-Gliszczynski et al., 2006b) . The purpose of this work was to determine whether Mrp2 is responsible for FEX biliary excretion in mice, and whether species differences in FEX biliary excretion exist between mice and rats. Furthermore, the possibility for the involvement of other transport mechanisms beyond Mrp2, P-gp and Bcrp in FEX biliary excretion was investigated with the employment of P-gp and Bcrp inhibitor GF120918 (GW918) in Mrp2-knockout mice.
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Material and Methods
Chemicals. FEX, taurocholate, and Krebs-Henseleit buffer packets were purchased from Sigma Chemical Co. (St. Louis, MO). GW918 was a gift from GlaxoSmithKline (Research Triangle Park, NC). All other chemicals were of reagent grade and were readily available from commercial sources.
Animals. Male C57BL/6 (B6) wild-type and Abcc2(-/-) (Mrp2KO) mice (25-30g) were provided by Eli Lilly and Co. Mrp2KO mice were generated as described previously (Nezasa et al., 2006 Single-Pass Liver Perfusion Study. In mice, the gallbladder was cannulated with PE-10 tubing, and both the portal vein and inferior vena cava above the liver were cannulated with a 20G catheter (Nezasa et al., 2006) . After a ~15-min pre-perfusion period (FEX-free Krebs-Henseleit buffer with 5 µM taurocholate; flow rate = 5 ml/min), single-pass perfusion of the liver was continued for 60 min with buffer containing 0.5 µM FEX and 10 µM GW918 or vehicle. Perfusate outflow and bile were collected in toto every 10 min. Rat livers were perfused in a similar, single-pass manner with Krebs-Henseleit buffer except that the common bile duct was cannulated with PE-10 tubing and the perfusate flow rate was 30 ml/min. 
Results and Discussion
The biliary excretion rate of FEX was decreased 85% in Mrp2KO mice compared to wild-type B6 mouse livers; GW918 decreased FEX biliary excretion rate ~45% in B6 and ~40% in Mrp2KO mouse livers compared to vehicle controls ( Figure 1A ; Table 1 ). FEX CL bile, int was significantly decreased in Mrp2KO compared to B6 mouse livers, but was not significantly affected by the co-infusion of 10 µM GW918 in either B6 or Mrp2KO mouse livers (Table 1 ). estimated to be 1.74 ml/hr/g liver (the difference between 3.01 and 1.27), and the combined contribution of P-gp and Bcrp was estimated to be ~0.3 ml/hr/g liver (the difference between 3.01 and 2.70 for B6, and 1.27 and1.03 for Mrp2KO livers) ( Table 1) .
These data clearly demonstrate that Mrp2 is the major transport protein mediating FEX biliary excretion in mice, that P-gp and Bcrp play a minor role, and that at least one other unidentified transport mechanism exists, which accounts for ~one-third of FEX CL bile, int .
Although previous studies indicated that P-gp transports FEX in vitro, and that P-gp was the major efflux mechanism for FEX in the mouse intestine and brain (Cvetkovic et al., 1999) , this is not the case in mouse liver. As exemplified with FEX, a positive result in an in vitro P-gp transport assay (Cvetkovic et al., 1999) does not imply necessarily that P-gp is the predominant transport pathway for the molecule in all organs that express P-gp.
Tissue-/organ-specific differences in the predominant transport protein for a drug, as reported previously for paclitaxel (Jurjen et al., 2006) , may be explained by transport multiplicity, including the affinity of a molecule for multiple transport proteins and the differential expression of these transport proteins in various tissues.
This article has not been copyedited and formatted. The final version may differ from this version. In contrast to mice, the biliary excretion rate and CL bile, int of FEX were comparable between Mrp2-deficient (TR -) and wild-type Wistar rat livers ( Figure 2A ; inter-species differences in drug transport complicate the in vitro-in vivo correlation and allometric scaling for drugs with predominantly transporter-mediated disposition.
Mean steady-state FEX concentrations in outflow perfusate (C ss, out ) were significantly higher, consistent with decreased hepatic extraction ratios, in livers from Mrp2KO relative to B6 mice ( Figure 1B ; GW918 is a more potent inhibitor of P-gp than Bcrp by an order of magnitude, thus concentrations known to inhibit Bcrp in mouse liver perfusions would also have inhibited P-gp transport (de Bruin et al., 1999) . The current experiments with GW918 were designed to inhibit both P-gp and Bcrp based on mouse liver perfusion studies in which 10  µM GW918 extensively impaired Bcrp-mediated biliary excretion of hepaticallygenerated 4-methylumbelliferyl sulfate (Zamek-Gliszczynski, 2006a ). In the presence of 10  µM GW918, FEX C liver , C liver,unbound and partitioning between perfusate and liver were significantly decreased in B6 mice (table 1) . FEX C liver , C liver,unbound and partitioning between perfusate and liver tended to be lower in the presence of GW918 in Mrp2KO mice, although the differences were not statistically significant. A similar trend was observed for the extraction ratios in both B6 and Mrp2KO mice (Table 1) . High concentration of GW918 (25 µM) has been reported to inhibit Oatp2-mediated hepatic uptake of digoxin (Lam and Benet, 2004) . Although GW918 did not significantly alter the CL bile, int of FEX in mouse livers (Table 1) , consistent with normal biliary excretion of FEX in P-gp-and Bcrp-knockout mice (Tahara et al., 2005) , the potential inhibition of Oatp-mediated hepatic uptake of FEX by GW918 cannot be ruled out.
In summary, this study demonstrated that FEX biliary excretion is mediated predominantly by Mrp2 in mice; the residual FEX biliary excretion in mice is due to unidentified transport mechanisms and, to a lesser extent, due to Bcrp and P-gp. In rats, the compensatory transport mechanisms responsible for FEX biliary excretion in the absence of Mrp2 remain to be identified. Alterations in liver sinusoidal transport proteins can have significant impact on the FEX biliary excretion as well. These findings highlight the complexities of in vivo drug transport processes, which are influenced by differences in transporter multiplicity and differential transport protein expression.
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